Mesenchymal stem cell, therapeutic agent for immune disease, and Anti-inflammatory agent

A technology of stem cells and therapeutic agents, applied in anti-inflammatory agents, animal cells, allergic diseases, etc., can solve problems such as hindering the resistance of infectious diseases

Pending Publication Date: 2021-07-23
ROHTO PHARM CO LTD +1
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of the drugs used to suppress autoimmune reactions also hinder the body's resistance to infect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesenchymal stem cell, therapeutic agent for immune disease, and Anti-inflammatory agent
  • Mesenchymal stem cell, therapeutic agent for immune disease, and Anti-inflammatory agent
  • Mesenchymal stem cell, therapeutic agent for immune disease, and Anti-inflammatory agent

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0076] (Method for preparing mesenchymal stem cells)

[0077] The method for producing mesenchymal stem cells with high kynurenine production or kynurenine secretion is not particularly limited, and for example, it can be produced as follows. That is, mesenchymal stem cells can be isolated and cultured from tissues such as adipose, umbilical cord, and bone marrow according to methods known to those skilled in the art, and the IDO expression can be used as an index to separate and obtain kynurenine using a cell sorter, magnetic beads, etc. Cells with high production or secretion of kynurenine. In addition, mesenchymal stem cells with high kynurenine production or kynurenine secretion in mesenchymal stem cells can also be obtained by culturing using a specific medium. In the cell population obtained by induction, preferably 50% or more of the cell population is cells with high kynurenine production or kynurenine secretion, and more preferably 70% or more is kynurenine productio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention addresses the problem of providing a novel therapeutic agent for an immune disease and a novel therapeutic agent for an anti-inflammatory agent. The present invention which can solve the problem is a mesenchymal stem cell characterized by being capable of producing kynurenine in a large amount or capable of secreting kynurenine in a large amount. The present invention also includes a mesenchymal stem cell which is characterized by being capable of producing kynurenine, which is synthesized from tryptophan with IDO induced in a cell by the treatment with IFNgamma, in a large amount or being capable of secreting the kynurenine in a large amount, and a mesenchymal stem cell which is characterized in that the JAK/STAT pathway thereof is enhanced in a steady state.

Description

technical field [0001] The present invention relates to mesenchymal stem cells, therapeutic agents for immune diseases and anti-inflammatory agents. Background technique [0002] An immunodeficiency disorder is an infection that occurs because the immune system does not work properly, or has multiple recurrences, or worsens symptoms, or persists for a long time. In the case of an immunodeficiency disease, the ability of the immune system to protect the body from foreign enemies such as bacteria, viruses, and fungi, and from abnormal cells such as cancer cells, is impaired. As a result, infections and cancers caused by bacteria, viruses, and fungi that would not have occurred if the immune function was normal occur. [0003] Among the immunodeficiency diseases, there are congenital (primary) immunodeficiency diseases contracted at birth, and acquired (secondary) immunodeficiency diseases developed later due to a certain disease or the like. Acquired immunodeficiency disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61P29/00A61P37/06A61K35/51C12N5/0775C12N15/09
CPCA61K35/51A61P29/00C12N15/09A61P37/06
Inventor 黑木辉汤本真代长村登纪子
Owner ROHTO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap